Ultragenyx药业 RARE 深 沪
已收盘 04-02 16:00:00 美东时间
22.45
+1.030
+4.81%
华盛通- 最 高22.45
- 今 开21.05
- 成交量 177.25万股
- 最 低 20.79
- 昨 收 21.42
- 总市值 22.07亿
- 52周最高 42.37
- 市盈率 静 --
- 换手率 1.80%
- 52周最低 18.29
- 委 比 -66.30%
- 总股本 9831.72万
- 历史最高 179.647
- 量 比 0.69
- 振 幅 7.75%
- 历史最低 18.29
- 每 手 1
- 风险率 5.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ultragenyx BLA for UX111 Accepted for FDA Review
Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On April 2, 2026, U...
04-02 21:44
Ultragenyx Pharmaceutical Receives FDA Clearance For Its Investigational New Drug Application For UX016 To Treat GNE Myopathy
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX016, an investigational small molecule
03-30 20:31
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $25
Goldman Sachs analyst Salveen Richter downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Buy to Neutral and lowers the price target from $61 to $25.
03-25 01:26
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. granted 10,839 restricted stock units to two newly hired non-executive officers, vesting over four years. The awards, made under the Ultragenyx Employment Inducement Plan, were approved by the company’s compensation committee and align with Nasdaq Listing Rule 5635(c)(4). Ultragenyx focuses on developing therapies for rare and ultra-rare diseases and is led by a team experienced in rare disease drug development.
03-20 20:30
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
UPDATE 1-Ultragenyx's gene therapy helps control ammonia levels in late-stage study
UPDATE 1-Ultragenyx's gene therapy helps control ammonia levels in late-stage study Adds details throughout March 12 (Reuters) - Ultragenyx Pharmaceutical RARE.O said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inh
03-12 20:46
Ultragenyx's gene therapy helps control ammonia levels in late-stage study
Ultragenyx's gene therapy helps control ammonia levels in late-stage study March 12 (Reuters) - Ultragenyx Pharmaceutical RARE.O said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder. (Reporting by Pa
03-12 20:36
U.S. RESEARCH ROUNDUP-Aerovironment, Bumble, Lumentum Holdings.
U.S. RESEARCH ROUNDUP-Aerovironment, Bumble, Lumentum Holdings. March 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Thursday, including Aerovironment, Bumble and Lumentum Holdings. HIGHLIGHTS * Aerovironment Inc AVAV.O : Je
03-12 15:49
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
Ultragenyx Pharmaceutical Inc. announced positive results from its Phase 3 Enh3ance study of DTX301, an investigational AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency. At Week 36, DTX301-treated patients showed a statistically significant 18% reduction in 24-hour plasma ammonia compared to placebo. Eight of nine patients with abnormal ammonia levels at baseline reached normal levels and maintained them during treatment. Patient...
03-12 12:30
